Strategic Partnerships Identify opportunities to partner with large pharma players and contract manufacturing organizations for shared development of high-fidelity vaccines, leveraging Vaxcyte’s XpressCF cell-free platform to accelerate timelines and reduce manufacturing risk.

PCV Franchise Expansion Leverage the broad-spectrum coverage of VAX-31 and VAX-24 to target pediatric and adult pneumococcal vaccination programs, offering collaboration on clinical development, regulatory strategy, and co-promotion with public health initiatives.

Infectious Disease Pipeline Explore licensing or collaboration on VAX-A1 (Group A Strep) and VAX-GI (Shigella) to diversify portfolio, address unmet needs in bacterial infections, and create cross-sell opportunities with immunology and infectious disease teams.

Financial & Strategic Investors Present the company’s strong cash position and substantial funding runway to potential strategic investors and partners, highlighting potential co-development or milestone-based financing to advance late-stage programs.

Evidence-Driven Value Offer detailed clinical and platform-value analytics to buyers, emphasizing the acceleration potential of XpressCF, protection against antibiotic resistance trends, and the unique conjugation tech as a competitive differentiator for collaboration discussions.